The Acute Liver Failure drugs in development market research report provides comprehensive information on the therapeutics under development for Acute Liver Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Acute Liver Failure. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Acute Liver Failure - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Acute Liver Failure and features dormant and discontinued products.

GlobalData tracks 31 drugs in development for Acute Liver Failure by 26 companies/universities/institutes. The top development phase for Acute Liver Failure is preclinical with 17 drugs in that stage. The Acute Liver Failure pipeline has 27 drugs in development by companies and four by universities/ institutes. Some of the companies in the Acute Liver Failure pipeline products market are: Genfit, Glycan Therapeutics and Shanghai Hexaell Biotech.

The key targets in the Acute Liver Failure pipeline products market include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1), Interleukin 22 Receptor (IL22R), and Dual Specificity Mitogen Activated Protein Kinase Kinase 4 (JNK Activating Kinase 1 or MAPK/ERK Kinase 4 or SAPK/ERK Kinase 1 or Stress Activated Protein Kinase Kinase 1 or c Jun N Terminal Kinase Kinase 1 or MEK4 or MAP2K4 or EC 2.7.12.2).

The key mechanisms of action in the Acute Liver Failure pipeline product include High Mobility Group Protein B1 (High Mobility Group Protein 1 or High Mobility Group Protein Box 1 or HMGB1) Inhibitor with two drugs in Preclinical. The Acute Liver Failure pipeline products include nine routes of administration with the top ROA being Intravenous and eight key molecule types in the Acute Liver Failure pipeline products market including Cell Therapy, and Small Molecule.

Acute Liver Failure overview

Acute liver failure is a rare but life-threatening condition that occurs when the liver loses most of its function in a short period of time. It can be caused by various factors, such as viral infections, drug overdose, autoimmune diseases, or metabolic disorders. Some of the common signs and symptoms of acute liver failure are jaundice, bleeding, confusion, and coma. Acute liver failure requires urgent medical attention and may need a liver transplant in some cases. Treatment options depend on the cause and severity of the condition.

For a complete picture of Acute Liver Failure’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.